Guggenheim Starts Coverage On Sienna Biopharmaceuticals (SNNA) with $21 Target; Blackrock Florida Municipal 2020 Term Trust (BFO) Sentiment Is 2.5

December 6, 2017 - By Marie Mckinney

The stock increased 0.27% or $0.04 during the last trading session, reaching $14.82. About 296 shares traded. BlackRock Florida Municipal 2020 Term Trust (BFO) has declined 0.62% since December 6, 2016 and is downtrending. It has underperformed by 17.32% the S&P500.

Among 5 analysts covering Sienna Biopharmaceuticals (SNNA), 4 have Buy rating, 0 Sell and 1 Hold. Therefore 80% are positive. Sienna Biopharmaceuticals has $50 highest and $28.0 lowest target. $34’s average target is 66.26% above currents $20.45 stock price. Sienna Biopharmaceuticals had 5 analyst reports since August 21, 2017 according to SRatingsIntel. The firm earned “Buy” rating on Monday, August 21 by J.P. Morgan. The stock of Sienna Biopharmaceuticals, Inc. (NASDAQ:SNNA) earned “Hold” rating by Guggenheim on Tuesday, December 5.

Naples Global Advisors Llc holds 0.22% of its portfolio in BlackRock Florida Municipal 2020 Term Trust for 40,854 shares. Mackay Shields Llc owns 203,891 shares or 0.13% of their US portfolio. Moreover, North Star Investment Management Corp. has 0.04% invested in the company for 19,500 shares. The Us-based Ancora Advisors Llc has invested 0.02% in the stock. Sit Investment Associates Inc, a Minnesota-based fund reported 47,670 shares.

The stock decreased 0.39% or $0.08 during the last trading session, reaching $20.45. About 2,103 shares traded. Sienna Biopharmaceuticals, Inc. (SNNA) has 0.00% since December 6, 2016 and is . It has underperformed by 16.70% the S&P500.

Sienna Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes topical products for medical dermatology and aesthetics markets in North America. The company has market cap of $407.59 million. The companyÂ’s lead product candidates include SNA-120, a TrkA inhibitor, which is in Phase 2b clinical development for the treatment of pruritus, itch, and neurogenic inflammation associated with psoriasis; and SNA-125, a dual JAK3/TrkA inhibitor that is in pre-clinical study for the treatment of atopic dermatitis, psoriasis, and pruritus. It currently has negative earnings. It also develops SNA-001, a photoparticle therapy, which is in pivotal clinical trials for the treatment of acne vulgaris and the reduction of unwanted light-pigmented hair.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter:


Twitter Auto Publish Powered By : XYZScripts.com